The solvents used in conventional taxane formulations are associated with increased toxicity, prolonged infusion times, need for steroid premedication, and a potential adverse effect on treatment efficacy. Enhanced-delivery taxanes (EDTs) include the first-generation agent nab-paclitaxel (ABI-007, Abraxane), a nanoparticle-sized, albumin-bound paclitaxel formulation that is approved for use in metastatic breast cancer. In a phase III trial in this setting, nab-paclitaxel given on an every-3-week schedule was shown to result in improved efficacy and reduced neutropenia compared with conventional paclitaxel and was associated with no severe hypersensitivity reactions despite the absence of routine steroid premedication. A recent randomized phase II trial has yielded promising findings with weekly nab-paclitaxel compared with docetaxel in the first-line treatment of metastatic disease. Second-generation EDTs, which seek both to exploit the enhanced permeability and retention in tumors and avoid drug micelle trapping, include paclitaxel poliglumex and the injectable emulsion formulation Tocosol paclitaxel. These agents have shown activity in early phase trials.
|Original language||English (US)|
|Number of pages||6|
|Issue number||5 SUPPL. 4|
|State||Published - May 2008|
ASJC Scopus subject areas